A phase Ib trial using the glutaminase inhibitor teleglenastat (CB-839) in combination with RT in IDH-mutant grade 2–3 astrocytomas demonstrated acceptable safety profiles80,81. This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).